Efimosfermin alfa
Based on 1 Customer Validation
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99%
- CAS. Nr.: 2765640-39-7
- Molecular Weight:89.11 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Species Reactivity
Human
In Vitro
Efimosfermin alfa works by activating the FGFR1c/β-Klotho complex.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
FPIA_FC-[PROTEIN]2
Verified Bioactivity
-
Measured in a cell proliferation assay using NIH-3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 0.3816 μg/mL in the presence of 1.25μg/mL Klotho beta, corresponding to a specific activity is 2.62×10^3 units/mg.
Chemical Information
-
CAS. Nr. 2765640-39-7
-
Appearance Liquid
-
Molecular Weight 89.11 kDa
-
Color Colorless to light yellow
-
SMILES
[Efimosfermin alfa]
-
Synonyms
BOS-580; LLF580
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Loomba R, et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2025;10(8):734-745. [Content Brief]
[2]. Cui X, et al. Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. Front Pharmacol. 2025 Apr 22;16:1510322. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Efimosfermin alfa Related Classifications
HY-P990964 Related Classifications
Powered by Bioz